1. ¹Department of Urology, Case Medical Center, Cleveland, OH, USA
2. ²Department of Urology, Middlesex Hospital, London, UK

Correspondence: Dr MI Resnick, Department of Urology, Case Medical Center, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA. E-mail: martin.resnick@case.edu

Received 19 September 2006; Accepted 11 October 2006; Published online 9 January 2007.

Abstract

This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Q_max) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged 50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Q_max increased significantly from baseline at day 8 with alfuzosin (P<0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P=0.07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Q_max and LUTS maintained through 1 month of treatment.